Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has...